Bispecific antibody-derived molecules to target persistent HIV infection
HIV infection persists despite durable and potent antiviral therapy. To target persistent HIV infection, one major strategy aims to induce HIV provirus expression using latency reversing agents and then eliminate these reservoir cells via immune responses enhanced by treatment with antibody-derived...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-09-01
|
| Series: | Journal of Virus Eradication |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664022000218 |
| _version_ | 1811182475614879744 |
|---|---|
| author | Jeffrey L. Nordstrom Guido Ferrari David M. Margolis |
| author_facet | Jeffrey L. Nordstrom Guido Ferrari David M. Margolis |
| author_sort | Jeffrey L. Nordstrom |
| collection | DOAJ |
| description | HIV infection persists despite durable and potent antiviral therapy. To target persistent HIV infection, one major strategy aims to induce HIV provirus expression using latency reversing agents and then eliminate these reservoir cells via immune responses enhanced by treatment with antibody-derived bispecific molecules. The specificities of anti-HIV-1 envelope monoclonal antibodies have been incorporated into bispecific molecules that can recognize infected cells and recruit cytotoxic immune cells to eliminate them. This concept seeks to engineer a unique and potent effector response based on the opportunity to target conserved viral epitopes on infected cells, and recruit broad populations of immune effector cells that are not limited by major histocompatibility complex restrictions or other programmed specificity constraints. This article provides a review of bispecific DART® molecules and other dual-specificity antibody-based molecules that function by co-engaging CD3-expressing T cells or CD16A-expressing NK cells with HIV-1-infected cells. |
| first_indexed | 2024-04-11T09:33:00Z |
| format | Article |
| id | doaj.art-0ef0c732729d4d928735151b31f26fb4 |
| institution | Directory Open Access Journal |
| issn | 2055-6640 |
| language | English |
| last_indexed | 2024-04-11T09:33:00Z |
| publishDate | 2022-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Virus Eradication |
| spelling | doaj.art-0ef0c732729d4d928735151b31f26fb42022-12-22T04:31:47ZengElsevierJournal of Virus Eradication2055-66402022-09-0183100083Bispecific antibody-derived molecules to target persistent HIV infectionJeffrey L. Nordstrom0Guido Ferrari1David M. Margolis2MacroGenics, Rockville, MD, 20850, USADepartment of Surgery, Duke University Medical Center, Durham, NC, USA; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC, USAUNC HIV Cure Center and Departments of Medicine, Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Corresponding author.HIV infection persists despite durable and potent antiviral therapy. To target persistent HIV infection, one major strategy aims to induce HIV provirus expression using latency reversing agents and then eliminate these reservoir cells via immune responses enhanced by treatment with antibody-derived bispecific molecules. The specificities of anti-HIV-1 envelope monoclonal antibodies have been incorporated into bispecific molecules that can recognize infected cells and recruit cytotoxic immune cells to eliminate them. This concept seeks to engineer a unique and potent effector response based on the opportunity to target conserved viral epitopes on infected cells, and recruit broad populations of immune effector cells that are not limited by major histocompatibility complex restrictions or other programmed specificity constraints. This article provides a review of bispecific DART® molecules and other dual-specificity antibody-based molecules that function by co-engaging CD3-expressing T cells or CD16A-expressing NK cells with HIV-1-infected cells.http://www.sciencedirect.com/science/article/pii/S2055664022000218 |
| spellingShingle | Jeffrey L. Nordstrom Guido Ferrari David M. Margolis Bispecific antibody-derived molecules to target persistent HIV infection Journal of Virus Eradication |
| title | Bispecific antibody-derived molecules to target persistent HIV infection |
| title_full | Bispecific antibody-derived molecules to target persistent HIV infection |
| title_fullStr | Bispecific antibody-derived molecules to target persistent HIV infection |
| title_full_unstemmed | Bispecific antibody-derived molecules to target persistent HIV infection |
| title_short | Bispecific antibody-derived molecules to target persistent HIV infection |
| title_sort | bispecific antibody derived molecules to target persistent hiv infection |
| url | http://www.sciencedirect.com/science/article/pii/S2055664022000218 |
| work_keys_str_mv | AT jeffreylnordstrom bispecificantibodyderivedmoleculestotargetpersistenthivinfection AT guidoferrari bispecificantibodyderivedmoleculestotargetpersistenthivinfection AT davidmmargolis bispecificantibodyderivedmoleculestotargetpersistenthivinfection |